Information Provided By:
Fly News Breaks for February 3, 2020
AIMT
Feb 3, 2020 | 08:11 EDT
Baird analyst Brian Skorney noted Aimmune received FDA approval for its peanut allergy drug, Palforzia and said he is encouraged buy its clean label and management's well-informed launch plan. The analyst noted the cost of the drug is at the high end of expectations but he still thinks they will achieve good insurance reimbursement. He expects the drug to have a strong uptake and believes they are well positioned to help satisfy the unmet peanut allergy need. Skorney reiterated his Outperform rating and $64 price target on Aimmune shares.
News For AIMT From the Last 2 Days
There are no results for your query AIMT